Beta Bionics, Inc., a commercial-stage medical device company, has recently disclosed a change in ownership through a Form 4 filing. This filing, submitted to the Securities and Exchange Commission, reported that an officer of the company sold shares of the company’s common stock during the preceding reporting period. Notably, the transaction was conducted under a Rule 10b5‑1 trading plan, a mechanism that allows company insiders to sell shares at predetermined times to avoid accusations of insider trading. Despite the sale, the officer’s post‑transaction holdings increased, indicating a continued commitment to the company.
Beta Bionics, Inc. is engaged in the design, development, and commercialization of innovative solutions aimed at enhancing the health and quality of life for insulin-requiring individuals with diabetes. The company’s flagship product, the iLet Bionic Pancreas, is an insulin delivery device designed for the treatment of type 1 diabetes in adults and children aged six years and older. Additionally, Beta Bionics is developing the Patch Pump, an insulin pump that adheres directly to the skin, eliminating the need for tubing. The company is also working on the Bihormonal iLet, which combines automated delivery of insulin and glucagon, and is exploring the use of the iLet for treating insulin-dependent type-2 diabetes.
In terms of strategic partnerships, Beta Bionics has entered into a collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation. Furthermore, the company has a development and commercialization agreement with Abbott Diabetes Care Inc. to advance an automated insulin delivery system.
Financially, Beta Bionics, Inc. is listed on the Nasdaq under the Health Care sector. As of September 10, 2026, the company’s close price was $16.57, with a 52-week high of $32.71 recorded on November 25, 2025, and a 52-week low of $8.80 on April 9, 2026. The company’s market capitalization stands at approximately $745.48 million. However, the price-to-earnings ratio is currently negative at -8.66, reflecting the company’s financial performance and market valuation.
Beta Bionics, Inc. was incorporated in 2015 and is headquartered in Irvine, California. The recent ownership change and ongoing product development efforts highlight the company’s dynamic position within the medical device industry, particularly in the realm of diabetes management solutions.
